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Abstract
Background: Cholinesterase inhibition is a vital target for the development of novel and mechanism based
inhibitors, owing to their role in the breakdown of acetylcholine (ACh) neurotransmitter to treat various
neurological disorders including Alzheimer’s disease (AD). Similarly, free radicals are implicated in the progression of
various diseases like neurodegenerative disorders. Due to lipid solubility and potential to easily cross blood brain
barrier, this study was designed to investigate the anticholinesterase and antioxidant potentials of the standardized
essential oils from the leaves and flowers of Polygonum hydropiper.
Methods: Essential oils from the leaves (Ph.LO) and flowers (Ph.FO) of P. hdropiper were isolated using Clevenger
apparatus. Oil samples were analyzed by GC-MS to identify major components and to attribute the antioxidant and
anticholinesterase activity to specific components. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)
inhibitory potentials of the samples were determined following Ellman’s assay. Antioxidant assays were performed
using 1,1-diphenyl,2-picrylhydrazyl (DPPH), 2,2-azinobis[3-ethylbenzthiazoline]-6-sulfonic acid (ABTS) and hydrogen
peroxide (H2O2) free radical scavenging assays.
Results: In the GC-MS analysis 141 and 122 compounds were indentified in Ph.LO and Ph.FO respectively.
Caryophylene oxide (41.42 %) was the major component in Ph.FO while decahydronaphthalene (38.29 %) was
prominent in Ph.LO. In AChE inhibition, Ph.LO and Ph.FO exhibited 87.00** and 79.66***% inhibitions at 1000 μg/ml
with IC50 of 120 and 220 μg/ml respectively. The IC50 value for galanthamine was 15 μg/ml. In BChE inhibitory
assay, Ph.LO and Ph.FO caused 82.66*** (IC50 130 μg/ml) and 77.50***% (IC50 225 μg/ml) inhibitions respectively at
1000 μg/ml concentration. In DPPH free radical scavenging assay, Ph.LO and Ph.FO exhibited IC50 of 20 and 200 μg/ml
respectively. The calculated IC50s were 180 & 60 μg/ml for Ph.LO, and 45 & 50 μg/ml for Ph.FO in scavenging of ABTS
and H2O2 free radicals respectively.
Conclusions: In the current study, essential oils from leaves and flowers of P. hydropiper exhibited dose dependent
anticholinesterase and antioxidant activities. Leaves essential oil were more effective and can be subjected to further
in-vitro and in-vivo anti-Alzheimer’s studies.
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Background
The cholinergic concept of Alzheimer’s disease (AD)
was initially resulted from postmortem studies of the
brain [1, 2], which ultimately led to the development of
new drugs based on the inhibition of the key enzymes
acetylcholinesterase (AChE) and butyrylcholinesterase
(BChE) [3, 4]. Therapy with such drugs resulted in a sig-
nificant improvement in cognitive functions and also
hampered the progression of the disease [5–7]. Two
cholinesterases, AChE encoded by gene on chromosome
7 and BChE encoded by gene on chromosome 3 occur
in the human central nervous system (CNS) [8, 9]. These
enzymes share about 65 % amino acid sequence hom-
ology even though coded on different genes [10]. In the
human brain BChE mostly appears to have a neuroglial
distribution, while AChE is principally located within
cholinergic axons and in the neuronal cell bodies. Both
enzymes are also present in neuritic plaques and tangles
in AD patients [11, 12]. The ratio of cholinesterases in
the human brain varies during the course of AD. A de-
cline of 10–15 % in the activity of AChE in the hippo-
campus and cerebral cortex has been reported in
advanced stages of the disease, whereas BChE activity in-
creases by 40–90 % [11, 13]. These changes in the ratio
of cholinesterases and variation in the level of the neuro-
transmitters in dementia must be considered in order to
optimize the therapeutic balance between AChE and
BChE inhibitions. This balance may be sustained via the
selective or non-selective inhibition of the enzymes. A
significant correlation between the inhibition of BChE
activity in the cerebrospinal fluid (CSF), but not AChE,
with an enhancement in cognitive performance in pa-
tients with mild to moderate AD after treatment with
rivastigmine (non-specific inhibitor of cholinesterases)
has been reported [14]. Experimental data also
revealed that BChE specific inhibitors not only raise
the levels of acetylcholine (ACh) in rats but also im-
prove memory in elderly rats [9, 15]. These findings
also signify that inhibition of BChE in addition to
AChE may be vital in the treatment of Alzheimer’s
type dementia.
A currently available drug like tacrine is observed
to have severe side effects like liver transaminase ele-
vations and gastrointestinal complainsts [16], and are
only useful in mild type of AD [17]. Therefore, it is
required to search new, safe and effective drug candi-
dates. Natural products are potential sources of novel
bioactive compounds and have an extensive history of
therapeutic utility since the establishment of human
era. Galanthamine, an anticholinestrase alkaloid was
isolated from snowdrop, and is approved for the ther-
apy of AD [18]. Research has been directed to study
the biological effects of plants traditionally used as
cholinesterase inhibitors [18, 19].
Free radicals including reactive oxygen species (ROS)
are implicated in a variety of disorders including neuro-
inflammation, gastritis, ischemic heart diseases, reperfu-
sion injury of tissues and atherosclerosis [20, 21]. Free
radicals generated during oxidation process are con-
verted to non-radical forms by catalase and hydroperoxi-
dase enzymes in living systems. But in case of excessive
radical generation or depletion of human immune sys-
tem natural antioxidants as free radical scavengers may
be required [22]. In Alzheimer’s patients and aging brain,
dysfunctional mitochondria generate free radicals, thus
lead to oxidative stress followed by oxidative damage
and pathological changes. β-amyloid (Aβ) is a powerful
originator of reactive oxygen and nitrogen species which
are primary initiators of oxidative harm thus effecting
neural, microglial, cerebrovascular cells and tissues [23].
Currently, available synthetic antioxidants including
gallic acid esters, tertiary butylated hydroquinone and
butylated hydroxy toluene (BHT) are associated with
adverse health consequences [24]. Numerous natural
bioactive compounds have been shown to possess
strong antioxidant potential which reveals that these
compounds have the ability to scavenge free radicals
inside the body and provide very low chances of
adverse effects [25, 26].
Among plants which have been investigated for the
treatment of neurodegenerative disorders, Polygonum
hydropiper is one of the most numerous genuses in the
family Polygonaceae which is abundant in North West of
Pakistan. This plant has a long history of use in folk
medicine as remedy for the treatment of a multiplicity of
disorders including inflammation, rheumatoid arthritis,
epilepsy, headache, colic pain, fever, chill, joint pain,
oedema and infectious diseases [27–29]. It is also used
as diuretic, CNS stimulant, anthelmintic, to treat insom-
nia, kidney diseases, hemorrhoids, hypertension and an-
gina [30]. Other species of Polygonaceae family have
been reported for their effectiveness in Parkinson’s dis-
ease [31], cerebral ischemia [32] and neuroprotective
agents [33]. We recently reported the solvent extracts of
P. hydropiper for antioxidant, anticholinestrase activities
and its potential effectiveness to treat neurodegenerative
disorders [29]. Volatile constituents of the essential oils
from P. hydropiper are expected to readily cross the
blood–brain barrier owing to their small molecular size
and lipophilic nature. Their volatile nature may also fa-
cilitate their administration in the form of inhalation
avoiding the alimentary canal with its attendant denatur-
ing of active molecular species.
Results
GC-MS analysis of samples
In GC, GC-MS analysis of Ph.LO, 141 compounds were
identified (as shown in Fig. 1) among which
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decahydronaphthalene (38.29 %), bicyclo [2.2.2]oct-2-
ene, 1,2,3,6-tetramethyl (36.33 %), β-elemene cis-1,3-dii-
sopropenyl-trans-4-vinyl-4-methylcyclohexane (6.81 %),
cis-geranylacetone (3.72 %), β-caryophyllene epoxide
(2.69 %) were in higher concentrations as shown in Fig. 2,
Table 1(A) (The details of all compounds identified in
the leaf oil is shown in Additional file 1: Table S1 in sup-
porting information). In analysis of Ph.FO, caryophylene
oxide (41.42 %), beta caryophyllene epoxide (18.17 %),
humulene oxide (16.09 %), β-elemene cis-1,3-diisoprope-
nyl-trans-4-vinyl-4-methylcyclohexane (4.76 %), 3,5-dii-
sopropenyl-1,1,2-trimethylcyclohexane (3.83 %) and
limonene (1.79 %) were in high concentrations as given
in Fig. 3, Table 1(B) (The details of all compounds
identified in the leaf oil is shown in Additional file 2:
Table S2 in supporting information).
Cholinesterase inhibition assays
The acetyl and butyrylcholinesterase inhibitions poten-
tials of essential oils isolated from leaves and flowers of
P. hydropiper are shown in Table 2.
Acetylcholinesterase (AChE) inhibition assay
In acetylcholinesterase (AChE) inhibition assay, essential
oils from leaves (Ph.LO) exhibited 87.00 ± 1.15**, 71.00 ±
0.57***, 63.66 ± 0.33***, 57.33 ± 0.88***, 52.00 ± 1.52***,
44.66 ± 1.20***, 36.50 ± 0.44*** and 28.00 ± 0.57*** % inhib-
ition at concentrations of 1000, 500, 250, 125, 100, 50, 25
and 12.50 μg/ml respectively. Likewise, essential oils from
flowers (Ph.FO), showed 79.66 ± 0.88***, 61.66 ± 1.20***
and 55.00 ± 1.00***, 49.00 ± 0.00***, 43.33 ± 1.45***, 35.00
± 0.57***, 28.00 ± 1.15*** and 21.66 ± 0.66***% inhibitions
at concentrations of 1000, 500, 250, 125, 100, 50, 25 and
12.50 μg/ml respectively. Highest AChE inhibitions from
standard drug galanthamine were 92.33 ± 0.33, 87.00 ±
1.20, 83.33 ± 0.66, 77.00 ± 0.00 and 72.00 ± 2.64 % at
concentration of 1000, 500, 250, 125 and 100 μg/ml
respectively. The IC50 for Ph.LO, Ph.FO and galanthamine
were 120, 220 and 15 μg/ml respectively.
Butyrylcholinesterase (BChE) inhibition assay
In Butyrylcholinesterase (BChE) inhibition assay, high-
est Ph.LO exhibited 82.66 ± 1.20***, 70.66 ± 0.88***,
61.00 ± 1.15*** and 52.00 ± 0.57***, 48.66 ± 1.20***,
(A)
(B)
Fig. 1 GC-MS chromatogram of essential oils from leaves (a) and flowers (b) of Polygonum hydropiper
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40.33 ± 0.88***, 31.00 ± 1.15*** and 20.66 ± 1.20***%
enzyme inhibitions at concentrations of 1000, 500,
250, 125, 100, 50, 25 and 12.50 μg/ml respectively.
Furthermore, Ph.FO showed 77.50 ± 0.44***, 64.00 ±
0.00***, 53.66 ± 0.88***, 46.66 ± 1.20***, 35.00 ± 0.16***,
27.33 ± 0.33***, 23.00 ± 1.15***, 18.00 ± 0.57***% BChE
inhibitions at concentrations of 1000, 500, 250, 125,
100, 50, 25 and 12.50 μg/ml respectively. Galantha-
mine revealed 96.00 ± 1.52, 92.33 ± 0.66, 89.33 ± 1.45,
86.66 ± 1.76, 81.00 ± 0.00, 77.66 ± 1.20, 70.00 ± 1.52
and 60.00 ± 0.57 % inhibitions at the same concentra-
tions. The IC50 calculated from dose response curve
were 130, 225 and 10 μg/ml for Ph.LO, Ph.FO and
galanthamine respectively.
Antioxidant assays
The antioxidant potentials of essential oils from leaves
and flowers of P. hydropiper were determined using
DPPH, ABTS and H2O2 free radicals. The results are
summarized in Table 3.
DPPH assay
In DPPH free radicals scavenging assay, Ph.LO exhibited
85.00 ± 1.15**, 79.50 ± 0.28***, 72.00 ± 1.04***, 65.16 ±
0.60*, 60.66 ± 0.92* and 53.50 ± 0.86, 46.66 ± 0.72 and
37.95 ± 0.29***% inhibitions at concentrations of 1000,
800, 400, 200, 100, 50, 25 and 12.50 μg/ml respectively.
For Ph.FO highest DPPH scavenging activities observed
were, 81.33 ± 0.72***, 70.16 ± 0.60***, 54.83 ± 2.92*** at
concentrations of 1000, 800 and 400 μg/ml respectively.
The IC50 calculated from dose–response curve were 20
and 200 μg/ml for Ph.LO & Ph.FO respectively. Ascorbic
acid demonstrated 91.90 ± 0.96, 87.08 ± 0.47, 79.85 ±
2.24, 68.36 ± 0.57 and 63.00 ± 1.15 % inhibitions at con-
centrations of 1000, 800, 400, 200 and 100 μg/ml re-
spectively attaining an IC50 of 5 μg/ml.
ABTS assay
In ABTS free radicals scavenging assay, 89.00 ± 0.50***,
73.16 ± 1.01***, 58.16 ± 1.09*, 42.66 ± 0.92, 27.50 ± 0.28,











Fig. 2 Major identified compounds in the GC-MS analysis of essential oils from leaves of Polygonum hydropiper (a) 1-Methyl-1,2,4-tri(prop-1-en-2-yl)cy-
clohexane (b) 4-(2,6,6-Trimethylcyclohex-2-enyl)butan-2-one (c) (Z)-6,10-dimethylundeca-5,9-dien-2-one (d) (Z)-1,2,3,5,6,7,8,8a-octahydro-1,4-dimethyl-7-
(prop-1-en-2-yl)azulene (e) 3-Cyclopropylbicyclo[4.1.0]heptan-7-yl)methanol (f) 3,7,11-Trimethyldodec-1-en-3-ol (g) 1,2,3,6-Tetramethylbicyclo[2.2.2]
oct-2-ene (h) (1R,5S,8R,9R)-4,4,8-trimethyltricyclo[6.3.1.0(1,5)]dodeca-2-en-9-ol (i) b-Caryophyllene epoxide (j) Decahydronaphthalene
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observed for Ph.LO at concentrations of 1000, 800 and
400, 200, 100, 50, 25 and 12.5 μg/ml respectively with
IC50 of 180 μg/ml. Likewise, Ph.FO exhibited a dose
dependent radicals scavenging activity of 87.33 ± 1.76***,
78.66 ± 0.88***, 72.00 ± 0.86, 66.00 ± 1.15, 51.33 ± 0.66,
45.16 ± 0.60, 38.50 ± 0.86 and 30.00 ± 0.00 % at 1000, 800
and 400 200, 100, 50, 25 and 12.5 μg/ml respectively.
The IC50 for Ph.FO was 45 μg/ml. The standard drug as-
corbic acid exhibited IC50 of 45 μg/ml at the same tested
concentrations.
Hydrogen peroxide assay
In H2O2 radicals scavenging assay, 79.00 ± 1.00***,
70.66 ± 0.88, 65.16 ± 1.96 and 58.00 ± 0.28, 47.50 ±
1.04, 42.50 ± 0.28, 33.16 ± 1.01 and 25.66 ± 0.66 %
scavenging effect was observed with Ph.LO at concen-
trations of 1000, 800, 400, 200, 100, 50, 25 and
12.5 μg/ml respectively. Whereas, Ph.FO showed
77.16 ± 0.44***, 71.66 ± 3.17*, 64.00 ± 0.00, 58.50 ± 0.76,
49.83 ± 0.44, 40.83 ± 0.92, 32.00 ± 2.30 and 21.83 ±
0.60 % inhibitions at concentrations of 1000, 800,
400, 200, 100, 50, 25 and 12.5 μg/ml respectively. The
IC50s were 60 and 50 μg/ml for Ph.LO and Ph.FO
respectively. In comparison, the standard drug ascor-
bic acid attain an IC50 of 7 μg/ml.
Discussion
Steam distillation, subsequently GC/MS and GC/FID
analysis were used to determine the chemical composi-
tions of essential oils from the leaves and flowers of P.
hydropiper. Chromatograms with the identified peaks
(Fig. 1) as well as the chemical structures of the major
identified compounds from leaves and flowers oils are
shown in Figs. 2 and 3 respectively. In GC, GC-MS ana-
lysis of Ph.LO, 141 compounds were identified among
which decahydronaphthalene (38.29 %) was in highest
concentration (Fig. 2, Table 1(A)). Likewise, in analysis
of Ph.FO, caryophylene oxide (41.42 %) was present in
highest concentration as given in Fig. 3, Table 1(B). The
number of identified compounds in Ph.LO were greater
than Ph.FO and both anticholinesterase and antioxidant
potentials of Ph.LO were observed to be higher than
Ph.FO. This is not astonishing that the chemical com-
position of essential oils greatly depends upon the genet-
ics, age, season and varies with environmental
conditions of the plant [34]. Up to the best of our
Table 1 User Chromatogram peaks list for major compounds identified in essential oils from leaves (A) and flowers (B) of Polygonum
hydropiper
RT Height Height % Area Area % Area Sum % Base Peak m/z Width
A
14.359 11039380 39.24 27045773 17.79 6.81 81.1 0.114
14.822 2441741 8.68 5347147 3.52 1.35 43.1 0.084
15.505 6158002 21.89 14751160 9.7 3.72 43.1 0.111
16.382 4049393 14.39 10136429 6.67 2.55 93.1 0.111
17.722 3399191 12.08 11251734 7.4 2.83 79.1 0.111
17.839 3697087 13.14 7865419 5.17 1.98 69.1 0.084
18.449 26630825 94.65 144220508 94.88 36.33 79.1 0.178
18.482 5054455 17.96 3502616 2.3 0.88 161.1 0.027
18.663 4507537 16.02 10670668 7.02 2.69 83 0.084
18.951 28135093 100 151997749 100 38.29 109.1 0.191
B
6.353 239671 6.66 548139 4.31 1.79 68.1 0.087
7.853 124166 3.45 277247 2.18 0.9 43.1 0.094
14.33 719035 19.97 1461208 11.5 4.76 81.1 0.077
16.369 196811 5.47 404002 3.18 1.32 43.1 0.07
16.751 181702 5.05 370460 2.91 1.21 43.1 0.074
18.319 3E + 06 71.93 5575945 43.87 18.17 43.1 0.084
18.61 531433 14.76 1176145 9.25 3.83 83 0.084
18.821 2E + 06 50.77 4937507 38.84 16.09 43.1 0.124
19.97 959858 26.66 2359693 18.56 7.69 43.1 0.087
21.433 4E + 06 100 12711263 100 41.42 43.1 0.134
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knowledge this is the most detailed report on the chem-
ical composition of essential oils from P. hydropiper.
Acetylcholinesterase (AChE) and butyrylcholinesterase
(BChE) are the key enzymes catalyzing the breakdown of
the important neurotransmitter acetylcholine (ACh) in the
nervous system to form acetate and choline [25]. ACh in-
sufficiency in the cerebral cortex of humans is among the
vital pathophysiologies observed in AD patients [35, 36].
An important tool for treating AD is to boost the level of
ACh in the brain by the administration of safe and effect-
ive AChE inhibitors [37]. Among the clinically approved
drugs, four are cholinesterase inhibitors including tacrine,
donepezil, rivastigmine and galantamine, whereas, the fifth
one is glutamatergic system modifier called memantine
(Fig. 4). Among these four drugs, the use of tacrine is lim-
ited due to hepatotoxic effects associated with it [38, 39].
Further, studies during clinical trials revealed that cholin-
esterase inhibitors may help AD patients to sustain their
ability to perform routine activities with less frequent
behavioral changes [40]. Other studies suggest that cholin-
esterase inhibitors may improve the cognitive perform-
ance of the AD patients even in the advanced stages of the
disease [41]. Consequently, cholinesterase inhibitors may
improve cognitive decline and thus reduce the emergence
of new behavioral turbulence.
In the current study, we observed that Ph.LO were most
effective against AChE causing 87.00 ± 1.15 % inhibition
followed by Ph.FO with 79.66 ± 0.88 % enzyme inhibition
at 1000 μg/ml. Among both oils, Ph.LO was more potent
with IC50 of 120 μg/ml, while the IC50 for Ph.FO was
220 μg/ml. The IC50 value for galanthamine was 15 μg/ml.
Both oils exhibited concentration dependent activity as
shown in Table 2. In BChE inhibitory assay, again Ph.LO
was more active causing 82.66 ± 1.20 % inhibition at
1000 μg/ml and IC50 of 130 μg/ml. Moreover, Ph.FO re-
vealed 77.50 ± 0.44 % inhibition at the same concentration
with IC50 of 225 μg/ml. Positive control inhibition was
96.00 ± 1.52 % at the same concentration and IC50 was
10 μg/ml. Presently, there is no complete preventative or
curative drug therapy available for AD, leaving the symp-
tomatic relief presented by AChE/BChE inhibitors as the
single approved therapeutic choice. Recently, galantha-
mine from Amaryllidaceae family is approved for clinical
use and has become a vital therapeutic option effective to
retard the process of neurological degeneration in AD.
Galanthamine provides an efficient symptomatic therapy
for AD patients and also delay the progression of the dis-
ease. Another isoquinoline alkaloid berberine, isolated
from Rhizoma coptidis and Cortex phellodendri is re-





Fig. 3 Major compounds identified in GC-MS analysis of essential oils from flower of Polygonum hydropiper (a) 1-methyl-4-(prop-1-en-2-yl)clohex-1-ene
(b) O-Hexylhydroxylamine (c) 1-methyl-2,4-dl(prop-1-en-2-yl)-1-vinylcyclohexane (d) 1-methyl-4-(2-methyloiran-2-yl)-7-oxa-bicyclo(4.1.0)heptane (e)
(-)-β-Caryophylleneepoxide (f) 1,1,2-trimethyl-3,5-di(prop-1-en-2-yl)cycloheaxane (g) (4E,7E)-1,5,9,9-tetramethyl-12-oxabicyclo[9.1.0]dodeca-4,7-diene
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like cerebral ischemia, schizophrenia, AD, depression
and anxiety [42, 43]. Berberine is reported to reduce
extracellular Aβ fabrication and BACE activity with-
out affecting the release of LDH in H4 neuroglioma
(APPNL-H4) cells [8]. Berberine therapy also reduces
cognitive dysfunction as indicated by decrease in er-
rors using MWM task in comparison to usual refer-
ence memory and memory retention (probe trial) in
APP transgenic mice. [44]. The essential oils in the
current study exhibited comparative percent inhibi-
tions with the standard drug in both assays. However,
the IC50 of essential oils were higher than that of an orally
administered standard drug galanthamine. We speculate
that the essential oils administered in the form of vapors
(aerosol) will have better availability than orally adminis-
tered drugs due to high lipid solubility and bypassing pre-
systemic metabolism. However, further in-vivo studies on
genetically modified animals’ models are required to con-
firm its in-vivo bioavailability and potential efficacy in
neurological disorders.
Modern research revealed that beta secretase en-
zyme (BACE1) catalyze the breakdown of amyloid
precursor protein (APP) to form ß-amyloid peptides
in AD brain, which provoke inflammatory process
with consequent release of free radicals oxygen spe-
cies causing neuronal damage [45–47]. Antioxidant
drugs may contribute to AD chemotherapy by attenu-
ation of the inflammatory pathways via scavenging of
free radicals [37]. In recent times, natural products
has got more attention as antioxidants as they are
safer and these substances could be supplied as food
components or in the form of pharmaceuticals for
human use [48]. Among those, essential oils from
aromatic and medicinal plants are well known to re-
veal antioxidant and cholinesterase inhibitory proper-
ties and thus can be very helpful in the treatment of
AD [49]. In DPPH assay, Ph.LO was most effective
causing 85.00 ± 1.15, 79.50 ± 0.28 and 72.00 ± 1.04 %
free radicals scavenging at concentrations of 1000,
800 and 400 μg/ml respectively. DPPH free radicals
Table 2 Results of AChE and BChE inhibitory activity of essential oils from leaves and flowers of Polygonum hydropiper
Sample % AChE inhibition Mean ± SEM (n = 3) % BChE inhibition Mean ± SEM (n = 3)
Concentration % inhibition IC50 Concentration % inhibition IC50
Essential oils from leaves (Ph.Lo) 12.5 28.00 ± 0.57*** 120 12.5 20.66 ± 1.20*** 130
25 36.50 ± 0.44*** 25 31.00 ± 1.15***
50 44.66 ± 1.20*** 50 40.33 ± 0.88***
100 52.00 ± 1.52*** 100 48.66 ± 1.20***
125 57.33 ± 0.88*** 125 52.00 ± 0.57***
250 63.66 ± 0.33*** 250 61.00 ± 1.15***
500 71.00 ± 0.57*** 500 70.66 ± 0.88***
1000 87.00 ± 1.15** 1000 82.66 ± 1.20***
Essential oils from flowers (Ph.Fo) 12.5 21.66 ± 0.66*** 220 12.5 18.00 ± 0.57*** 225
25 28.00 ± 1.15*** 25 23.00 ± 1.15***
50 35.00 ± 0.57*** 50 27.33 ± 0.33***
100 43.33 ± 1.45*** 100 35.00 ± 0.16***
125 49.00 ± 0.00*** 125 46.66 ± 1.20***
250 55.00 ± 1.00*** 250 53.66 ± 0.88***
500 61.66 ± 1.20*** 500 64.00 ± 0.00***
1000 79.66 ± 0.88*** 1000 77.50 ± 0.44***
Galanthamine (P. Control) 12.5 51.00 ± 0.00 15 12.5 60.00 ± 0.57 10
25 60.50 ± 0.44 25 70.00 ± 1.52
50 65.66 ± 0.33 50 77.66 ± 1.20
100 72.00 ± 2.64 100 81.00 ± 0.00
125 77.00 ± 0.00 125 86.66 ± 1.76
250 83.33 ± 0.66 250 89.33 ± 1.45
500 87.00 ± 1.20 500 92.33 ± 0.66
1000 92.33 ± 0.33 1000 96.00 ± 1.52
Results were expressed as means ± S.E.M. The P values less than 0.05 were considered as statistically significant. Values significantly different when compared to
slandered drug (Galanthamine) at the same concentration i.e. *: P < 0.05, **: P < 0.01 and ***: P < 0.001
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scavenging activity of Ph.FO was 81.33 ± 0.72, 70.16 ±
0.60 and 54.83 ± 2.92 % at 1000, 800 and 400 μg/ml
respectively. Ph.LO and Ph.FO exhibited IC50 of 20
and 200 μg/ml respectively, whereas, the IC50 of as-
corbic acid was 5 μg/ml (Table 3). Likewise, In ABTS
assay Ph.LO demonstrated 89.00 ± 0.50 % inhibitions
of free radicals followed by Ph.FO with 87.33 ± 1.76 %
inhibition at 1000 μg/ml. All fractions showed con-
centration dependent activity. For both samples, the
IC50 values were 180 and 45 μg/ml respectively. In
H2O2 free radicals scavenging assay, 79.00 ± 1.00 and
77.16 ± 0.44 % inhibitions were observed for Ph.LO
and Ph.FO respectively at 1000 μg/ml. For these sam-
ples the IC50 were 60 and 50 μg/ml. Ph.LO was ob-
served to be more effective against all tested free
radicals. In both assays Ph.LO was more effective in
comparison to Ph.FO which can be attributed to the
presence of active compounds in Ph.LO. In the
current study, the percent inhibitions of essential oils
were comparative to standard drugs at the same
concentrations. Though the IC50 of oils were higher
than standard drugs, still the dual efficacy (anticholin-
esterase and antioxidant) of essential oils demonstrate
their potential effectiveness in neurological disorders.
Conclusions
Essential oils from P. hydropiper were investigated for
the first time for anticholinesterase and antioxidant
potentials. All samples exhibited concentration
dependent enzyme inhibitions and anti-radical activ-
ities with Ph.LO most affective. In GC, GC-MS ana-
lysis 144 and 122 compounds were identified in
Ph.LO and Ph.FO respectively. Further in-vivo studies
are required for possible use of these samples in neu-
rodegenerative disorders.
Material and methods
Collection of plant material
Fresh leaves of P. hydropiper were collected from Talash
Valley Dir (L) Pakistan in the month of September 2014.
Table 3 Antioxidant Potential of essential oils from Polygonum hydropiper leaves and flowers
Samples DPPH free radical scavenging ABTS free radical scavenging H2O2 free radical scavenging
Conc. μg/ml % inhibition IC50 % inhibition IC50 % inhibition IC50
Essential oils from leaves (Ph.LO) 12.5 37.95 ± 0.29*** 20 9.66 ± 1.33ns 180 25.66 ± 0.66 ns 60
25 46.66 ± 0.72ns 13.00 ± 1.15 ns 33.16 ± 1.01 ns
50 53.50 ± 0.86ns 25.66 ± 2.18 ns 42.50 ± 0.28 ns
100 60.66 ± 0.92* 27.50 ± 0.28 ns 47.50 ± 1.04 ns
200 65.16 ± 0.60* 42.66 ± 0.92 ns 58.00 ± 0.28 ns
400 72.00 ± 1.04*** 58.16 ± 1.09* 65.16 ± 1.96 ns
800 79.50 ± 0.28*** 73.16 ± 1.01*** 70.66 ± 0.88 ns
1000 85.00 ± 1.15** 89.00 ± 0.50*** 79.00 ± 1.00***
Essential oils from Flower (Ph.FO) 12.5 22.83 ± 0.72*** 200 30.00 ± 0.00 ns 45 21.83 ± 0.60 ns 50
25 28.00 ± 0.57*** 38.50 ± 0.86 ns 32.00 ± 2.30 ns
50 35.83 ± 0.60*** 45.16 ± 0.60 ns 40.83 ± 0.92 ns
100 42.33 ± 0.44*** 51.33 ± 0.66 ns 49.83 ± 0.44 ns
200 47.33 ± 1.30*** 66.00 ± 1.15 ns 58.50 ± 0.76 ns
400 54.83 ± 2.92*** 72.00 ± 0.86 ns 64.00 ± 0.00 ns
800 70.16 ± 0.60*** 78.66 ± 0.88*** 71.66 ± 3.17*
1000 81.33 ± 0.72*** 87.33 ± 1.76*** 77.16 ± 0.44***
Ascorbic Acid (Positive control) 12.5 45.00 ± 0.50 5 49.16 ± 0.60 10 46.66 ± 0.72 7
25 47.33 ± 1.30 56.50 ± 1.04 55. 16 ± 0.60
50 54.88 ± 1.30 63.16 ± 1.01 63.00 ± 0.00
100 63.00 ± 1.15 70.00 ± 0.00 68.58 ± 0.69
200 68.36 ± 0.57 75.45 ± 0.65 71.44 ± 0.58
400 79.85 ± 2.24 81.37 ± 0.64 76.45 ± 0.77
800 87.08 ± 0.47 88.37 ± 0.54 84.36 ± 0.64
1000 91.90 ± 0.96 94.30 ± 0.61 89.37 ± 0.65
Each value represent mean ± S.E.M of three independent experimental results. Values significantly different when compared to slandered drug (Ascorbic acid) at
the same concentration i.e. *: P < 0.05, **: P < 0.01 and ***: P < 0.001. ns: Values not significantly different in comparison to P. control
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The leaves were washed with distilled water to remove
any dust. Whereas, flowers of P. hydropiper were in full
bloom in the month of September 2014, in Talash valley
Dir lower Pakistan and were collected. Plant samples were
deposited at the herbarium, University of Malakand
Chakdara (Dir), Pakistan with voucher no (H.UOM.BG.107).
Isolation of the essential oils
Fresh leaves of P. hydropiper were macerated and
hydrodistilled using a Clevenger type apparatus sup-
plied with condenser. Distillation process was contin-
ued for 3 days at 100 °C, and the volatile oils
(yellowish in color) were collected in glass bottles.
Anhydrous sodium sulfate was used to remove water
after extraction [50]. Flowers of P. hydropiper were
hydro-distilled with a Likens–Nickerson-type appar-
atus using diethyl ether for 3 h. White to yellow color
obtained which was dried over anhydrous sodium
sulphate. Finally, the oils were properly sealed in glass
vials and stored in refrigerator at −30 °C before fur-
ther analysis.
Gas chromatography (GC) analysis
Essential oils samples were analyzed by means of an
Agilent USB-393752 gas chromatograph (Agilent
Technologies, Palo Alto, CA, USA) with HHP-5MS 5 %
phenylmethylsiloxane capillary column (30 m × 0.25 mm
× 0.25 μm film thickness; Restek, Bellefonte, PA) equipped
with an FID detector. The temperature of Oven was main-
tained at 70 °C for 1 min at first, and then increased at the
rate of 6 °C/min to 180 °C for 5 min and lastly at the rate
of 5 °C/min to 280 °C for 20 min. Injector and detector
temperatures were set at 220 °C and 290 °C, correspond-
ingly. Helium was used as carrier gas at a flow rate of
1 ml/min, and diluted samples (1/1000 in n-pentane, v/v)
of 1.0 μl were injected manually in the split-less mode.
Gas chromatography–mass spectrometry (GC/MS) analysis
GC/MS analysis of the oil samples were processed using
an Agilent USB-393752 gas chromatograph (Agilent
Technologies, Palo Alto, CA, USA) with a HHP-5MS
5 % phenylmethylsiloxane capillary column (30 m ×
0.25 mm × 0.25 μm film thickness; Restek, Bellefonte,
PA) outfitted with an Agilent HP-5973 mass selective
detector in the electron impact mode (Ionization energy:
70 eV) working under the same experimental conditions
as described for GC.
Identification of components
Oils major constituents were recognized by compari-
son of their retention times with those of authentic
compounds in the literature. Moreover, identification
was done via the spectral data obtained from the





















Fig. 4 Clinically available drugs for Alzheimer’s therapy
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the fragmentation pattern of the mass spectra with
data published in the literature [51, 52] or with mass
spectra from literature.
Chemical and drugs
For cholinesterase inhibition assay, AChE from Electric eel
(type-VI-S, code 1001596210) and BChE from equine
serum Lyophilized (code 101292670) were purchased
from Sigma-Aldrich GmbH USA. Enzyme substrates in-
cluding acetylthiocholine iodide (code 101303874) and
butyrylthiocholine Iodide (code 101334643) were pur-
chased from Sigma-Aldrich UK and Sigma-Aldrich
Switzerland respectively. Indicator substance, 5,5-dithio-
bis-nitrobenzoic acid (DTNB) code 101261619 was pur-
chased from Sigma-Aldrich Germany. Standard drug
galanthamine hydrobromide Lycoris Sp. (code G1660) was
purchased from Sigma-Aldrich France. For antioxidant as-
says, DPPH (code 101341986 Sigma Aldrich CHEMIE
GmbH USA), ABTS (code 1001551916 Sigma Aldrich
USA), K2S2O4 (Riedel-de Haen Germany) and Folin
Ciocalteu reagent (FCR) were acquired from Merck Co.
(Germany). Buffer system including (K2HPO4), (KH2PO4),
KOH and solvents used were of extra pure quality.
Anticholinesterase assays
AChE and BChE inhibitory potentials of the samples
were carried out following Ellman’s assay [53, 54].
Using this procedure, acetylthiocholine iodide or
butyrylthiocholine iodide are hydrolyzed by the re-
spective enzymes to form 5-thio-2-nitrobenzoate
anion which then form complex with DTNB and give
UV detectable yellow color compound.
Preparation of solutions
Oil samples were dissolved in phosphate buffer
(0.1 M) in concentrations of 12.5, 25, 50, 100, 125,
500 and 1000 μg/ml. Phosphate buffer (0.1 M with
8.0 ± 0.1 pH) was prepared by mixing K2HPO4
(17.4 g/L) and KH2PO4 (13.6 g/L) solution in a ratio
of 94 % and 6 % respectively. pH was adjusted using
potassium hydroxide. To prepare enzyme solutions,
AChE (518U/mg solid) and BChE (7-16U/mg) were
diluted in buffer solution (pH 8.0) up to final concen-
trations of 0.03 U/ml and 0.01 U/ml. Substrate solu-
tions including ATchI, BTchI (0.0005 M) and DTNB
(0.0002273 M), were prepared using distilled water
and were refrigerated at 8 °C until use. Standard drug
(galanthamine) dilutions were made in methanol.
Spectroscopic analysis
In each experiment, 5 μl enzyme solutions were added
to the cuvette and oil samples were added at the above
mentioned concentrations. Finally, DTNB reagent (5 μl)
was added to the cuvette and the resultant mixture was
incubated at 30 °C for 15 min using water bath. A sub-
strate solution (5 μl) was added at the end and absorb-
ance was measured at 412 nm using a double beam
spectrophotometer (Thermo electron corporation USA).
Negative control contained all components except oil
samples, while positive control galanthamine (10 μg/
ml) was used in the assay as standard cholinesterase
inhibitor. Change in absorbance along with the reac-
tion time was recorded for 4 h at 30 °C. The experi-
ments were performed in triplicate. Enzymes activity
and enzyme inhibition by control and tested samples
were determined from the rate of absorption with
change in time (V = ΔAbs /Δt) as; Enzyme inhibition
(%) = 100 - percent enzyme activity;
Enzyme activity %ð Þ ¼ 100  V
Vmax
Where (Vmax) is enzyme activity in the absence of in-
hibitor drug.
Antioxidant assays
DPPH free radicals scavenging assay
Free radicals scavenging ability of the essential oil
was determined following well established procedures
[29, 55]. Different dilutions (12.5, 50, 100, 200, 400,
800 and 1000 μg/ml) of essential oils (0.1 ml) were
added to 0.004 % methanolic solution of DPPH. After
30 min, absorbance was measured at 517 nm using
UV spectrophotometer (Thermo electron corporation,





Ascorbic acid was used as positive control. Where A0
characterize absorbance of control and A1 is the absorb-
ance of the essential oils. All experiments were per-
formed in triplicate and inhibition graphs were made
with the help of GraphPad prism program (GraphPAD,
San Diego, California, USA). Median inhibitory concen-
trations IC50 values were calculated using Microsoft
Excel programme.
ABTS free radicals scavenging assay
The ABTS free radical scavenging potential of samples
were evaluated using previously reported procedure [56].
The test is based on the ability of antioxidants present in
the sample to scavenge ABTS radicals leading to reduc-
tion. Using this procedure, solutions of ABTS 7 mM and
potassium persulphate (K2S2O4) 2.45 mM were mixed and
stored in dark place at room temperature for 12–16 h to
obtain a dark colored solution. This solution was diluted
using Phosphate buffer (0.01 M) pH 7.4 and absorbance
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value was adjusted to 0.70 at 734 nm. Finally, 300 μl solu-
tion of test sample was added to 3.0 ml of ABTS solution
in cuvette and was analyzed spectrophotometerically at
734 nm. The decline in absorbance was determined after
one minute of mixing the solutions and analysis was con-
tinued for 6 min. Ascorbic acid was used as positive con-
trol. The assay was repeated in triplicate and percentage
inhibition was calculated using formula:
% scavenging effect ¼ control absorbance ‐
sample absorbance =control absorbance  100
Hydrogen peroxide free radicals scavenging assay
The hydrogen peroxide scavenging activity of extracts
was determined using methods described previously
[57]. Using this method 2 mM hydrogen peroxide solu-
tion was prepared in 50 mM phosphate buffer having
pH of 7.4. Oil samples (0.1 ml) were taken in test tubes
and their volumes were increased to 0.4 ml using
50 mM phosphate buffer solution. Hydrogen peroxide
(0.6 ml) was added to the tubes and was vertexed. Ab-
sorbance of each sample was measured at 230 nm
against the blank after 10 min. Hydrogen peroxide scav-




Estimation of IC50 values
Concentrations of the oils which inhibited substrate hy-
drolysis (AChE and BChE) by 50 % (IC50) were calcu-
lated from dose response ratio using Microsoft Excel
program. In DPPH, ABTS and H2O2 the IC50 values
were calculated using the same procedure.
Statistical data analysis
All the assays were repeated in triplicate and values were
expressed as mean ± S.E.M. One way ANOVA followed
by Dunnett’s multiple comparison test was applied for
the comparison of positive control with the test group at
95 % confidence interval using GraphPad prism Software
USA. The P values less than 0.05 were considered as sta-
tistically significant.
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